SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Celgene-CELG -- Ignore unavailable to you. Want to Upgrade?


To: scaram(o)uche who wrote (293)4/8/1999 10:25:00 PM
From: Miljenko Zuanic  Respond to of 804
 
Rick,

Missed T in Cochexia:

Thalidomide (T) in the Symptomatic Treatment of Cachexia in Patients (Pts) with Terminal Cancer

General Poster Session: Stem Cell Transplantation/Cytokines
Date: "May 15, 1999"
Time: 8:00 AM - 12:00 PM
Location: Hall C (East Wing)



To: scaram(o)uche who wrote (293)4/10/1999 9:08:00 AM
From: bigg e  Read Replies (1) | Respond to of 804
 
FWIW....Believe CELG will receive favorable coverage in NEJM within next 45 days. Always a nice catalyst.